A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a
lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of
lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects
with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with
related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.